BioLineRXBLRX
Market Cap: $49.7M
About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Employees: 79
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
34% more capital invested
Capital invested by funds: $1.8M [Q1] → $2.42M (+$621K) [Q2]
11% more funds holding
Funds holding: 28 [Q1] → 31 (+3) [Q2]
0.21% more ownership
Funds ownership: 0.15% [Q1] → 0.35% (+0.21%) [Q2]
49% less call options, than puts
Call options by funds: $35K | Put options by funds: $69K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jones Trading Justin Walsh 64% 1-year accuracy 7 / 11 met price target | 222%upside $2 | Buy Initiated | 4 Sept 2024 |